Substance misuse in adults with primary tic disorders (P12-11.012)

Abstract

<h3>Objective:</h3> To estimate prevalence of substance use disorder (SUD) in adults with tics and characterize relationship with sex, age, psychiatric comorbidities and tic severity. <h3>Background:</h3> There are few data regarding SUD in adults with tics. One Swedish population-based study reported a high SUD-prevalence (15.9%) in people with Tourette syndrome (Virtanen et al, 2020). <h3>Design/Methods:</h3> From our Calgary and Paris Adult Tic Registry, we included adults with primary tic disorders who answered to the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool for substance use screening. For alcohol, tobacco, and cannabis, SUD was possible if the TAPS score was 2+. For illicit and prescription drugs, we used a cut-off of 1+ to identify problem use. We compared the prevalence of possible SUD in our cohort with the Swedish study’s results (Z-test). We looked for associations between possible SUD and age, sex, psychiatric comorbidities and tic severity using logistic/linear regression. <h3>Results:</h3> We included 139 participants (122 with Tourette syndrome; mean age: 32.5 years; 64.0% males; 53.2% Canadian, 46.8% French). A total of 28/139 (20.2%) had possible SUD for alcohol, 16/139 (11.5%) for tobacco and 15/139 (10.8%) for cannabis. For other substances: 7/139 (5.0%) were likely to have a problem use with cocaine/crack/methamphetamine, 1/139 (0.7%) with heroine, 1/139 (0.7%) with opioids, 11/139 (7.9%) with sedative drugs and 1/139 (0.7%) with stimulants for attention deficit/hyperactivity disorder (ADHD). Prevalences of possible overall-SUD (37%) and alcohol-SUD were higher than in the Swedish cohort (p=0.0142 and p&lt;0.00001). Total tic severity score was higher in people with possible SUD (p=0.017). Depression and anxiety were significantly associated with possible cannabis-related SUD (OR=3.5 and OR=7.2 respectively). Age, sex, comorbid ADHD and obsessive-compulsive disorder were not significantly associated with possible SUD. <h3>Conclusions:</h3> Thirty-seven % of adults with tic disorders have possible SUD related to alcohol, tobacco or cannabis, and require further diagnostic assessment. <b>Disclosure:</b> Ms. Nilles has received research support from French Gilles de la Tourette Association. Ms. Nilles has received research support from Owerko Centre of Alberta Children’s Hospital Research Institute. Ms. Nilles has received research support from Assistance Publique - Hôpitaux de Paris. Dr. Roze has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for merz. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving as a Consultant for orkyn. Dr. Roze has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for elivie. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for allergan. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Orkyn. Dr. Roze has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for elivie. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aguettant. The institution of Dr. Roze has received research support from merz. The institution of Dr. Roze has received research support from Orkyn. Dr. Roze has received research support from elivie. The institution of Dr. Roze has received research support from allergan. The institution of Dr. Roze has received research support from fondation desmarest. The institution of Dr. Roze has received research support from everpharma. Dr. Roze has received research support from AMADYS. The institution of Dr. Roze has received research support from ADCY5.org. The institution of Dr. Roze has received research support from agence nationale de la recherche. The institution of Dr. Roze has received research support from société française de médecine esthétique. The institution of Dr. Roze has received research support from dystonia medical research foundation. Andreas Hartmann has nothing to disclose. Dr. Worbe has nothing to disclose. The institution of Mr. Bendetowicz has received research support from Fondation Recherche Médicale. Dr. Szejko has nothing to disclose. Mrs. SERARI has nothing to disclose. Julian Fletcher has nothing to disclose. Dr. Martino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Martino has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merz Pharma Canada Ltd.. The institution of Dr. Pringsheim has received research support from Maternal Newborn Child and Youth Strategic Clinical Network. The institution of Dr. Pringsheim has received research support from Owerko Center of Alberta Children’s Hospital Research Institute. The institution of Dr. Pringsheim has received research support from Canadian Institutes of Health Research. The institution of Dr. Pringsheim has received research support from Public Health Agency of Canada.